Use of In Vitro Dynamic Colon Model (DCM) to Inform a Physiologically Based Biopharmaceutic Model (PBBM) to Predict the In Vivo Performance of a Modified-Release Formulation of Theophylline.

Stamatopoulos, Konstantinos; O'Farrell, Connor; Simmons, Mark J H; Batchelor, Hannah K; Mistry, Nena

Stamatopoulos, Konstantinos; O'Farrell, Connor; Simmons, Mark J H; Batchelor, Hannah K; Mistry, Nena.

Afiliación

Stamatopoulos K; Biopharmaceutics, DPD, MDS, GSK, David Jack Centre, Park Road, Ware SG12 0DP, UK.
O'Farrell C; School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Simmons MJH; School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Batchelor HK; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK.
Mistry N; Biopharmaceutics, DPD, MDS, GSK, David Jack Centre, Park Road, Ware SG12 0DP, UK.

Pharmaceutics ; 15(3)2023 Mar 09.

Article en En | MEDLINE | ID: mdl-36986743

Palabras clave

Dynamic Colon Model (DCM); PBBM; PBPK; SimCyp®; USP II; dissolution testing; in silico modelling; in vitro model; modified release (MR); pharmacokinetics; theophylline

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Pharmaceutics Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google